DE69831504T2 - Orale verabreichungsform enthaltend einen protonenpumpeninhibitor (z.b.pantoprazole) - Google Patents

Orale verabreichungsform enthaltend einen protonenpumpeninhibitor (z.b.pantoprazole) Download PDF

Info

Publication number
DE69831504T2
DE69831504T2 DE69831504T DE69831504T DE69831504T2 DE 69831504 T2 DE69831504 T2 DE 69831504T2 DE 69831504 T DE69831504 T DE 69831504T DE 69831504 T DE69831504 T DE 69831504T DE 69831504 T2 DE69831504 T2 DE 69831504T2
Authority
DE
Germany
Prior art keywords
pantoprazole
proton pump
form containing
pump inhibitor
administrative form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69831504T
Other languages
English (en)
Other versions
DE69831504D1 (de
Inventor
Rudolf Linder
Rango Dietrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Altana Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26042262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69831504(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1997154324 external-priority patent/DE19754324A1/de
Priority claimed from DE1998122549 external-priority patent/DE19822549A1/de
Application filed by Altana Pharma AG filed Critical Altana Pharma AG
Priority to DE69831504T priority Critical patent/DE69831504T2/de
Publication of DE69831504D1 publication Critical patent/DE69831504D1/de
Application granted granted Critical
Publication of DE69831504T2 publication Critical patent/DE69831504T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A61K9/025—Suppositories; Bougies; Bases therefor; Ovules characterised by shape or structure, e.g. hollow layered, coated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
DE69831504T 1997-12-08 1998-12-08 Orale verabreichungsform enthaltend einen protonenpumpeninhibitor (z.b.pantoprazole) Expired - Lifetime DE69831504T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE69831504T DE69831504T2 (de) 1997-12-08 1998-12-08 Orale verabreichungsform enthaltend einen protonenpumpeninhibitor (z.b.pantoprazole)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE1997154324 DE19754324A1 (de) 1997-12-08 1997-12-08 Neue Darreichungsform enthaltend einen säurelabilen Wirkstoff
DE1998122549 DE19822549A1 (de) 1998-05-20 1998-05-20 Neue Darreichungsform enthaltend einen säurelabilen Wirkstoff
DE69831504T DE69831504T2 (de) 1997-12-08 1998-12-08 Orale verabreichungsform enthaltend einen protonenpumpeninhibitor (z.b.pantoprazole)
PCT/EP1998/008036 WO1999029320A1 (en) 1997-12-08 1998-12-08 Novel administration form comprising an acid-labile active compound

Publications (2)

Publication Number Publication Date
DE69831504D1 DE69831504D1 (de) 2005-10-13
DE69831504T2 true DE69831504T2 (de) 2006-06-14

Family

ID=26042262

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69831504T Expired - Lifetime DE69831504T2 (de) 1997-12-08 1998-12-08 Orale verabreichungsform enthaltend einen protonenpumpeninhibitor (z.b.pantoprazole)
DE69821976T Expired - Lifetime DE69821976T2 (de) 1997-12-08 1998-12-08 Neue suppositoriumsform mit säureempfindliche wirkstoffe
DE69842173T Expired - Lifetime DE69842173D1 (de) 1997-12-08 1998-12-08 Neue Suppositoriumsform mit säureempfindlichem Wirkstoff

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69821976T Expired - Lifetime DE69821976T2 (de) 1997-12-08 1998-12-08 Neue suppositoriumsform mit säureempfindliche wirkstoffe
DE69842173T Expired - Lifetime DE69842173D1 (de) 1997-12-08 1998-12-08 Neue Suppositoriumsform mit säureempfindlichem Wirkstoff

Country Status (16)

Country Link
US (5) US6328993B1 (de)
EP (4) EP1037634B1 (de)
JP (2) JP4546643B2 (de)
AT (3) ATE260090T1 (de)
AU (2) AU748209B2 (de)
CA (2) CA2310585C (de)
DE (3) DE69831504T2 (de)
DK (2) DK1037607T3 (de)
EE (2) EE04800B1 (de)
ES (4) ES2249849T3 (de)
HU (2) HUP0100043A2 (de)
IL (3) IL136249A0 (de)
PL (2) PL195266B1 (de)
PT (1) PT1037607E (de)
SI (2) SI1037607T1 (de)
WO (2) WO1999029320A1 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
HUP0100043A2 (hu) * 1997-12-08 2001-08-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Savérzékeny hatóanyagot tartalmazó új gyógyszerforma
CA2344306A1 (en) * 1998-09-21 2000-03-30 Amato Pharmaceutical Products, Ltd. Oral drug delivery system for enhancing the bioavailability of active form of glycyrrhizin
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
TR200103527T2 (tr) 1999-06-07 2002-04-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Bir asit-labil aktif bileşik içeren yeni hazırlama ve uygulama şekli
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
KR100647901B1 (ko) * 1999-07-09 2006-11-17 보령제약 주식회사 세파클러-함유 서방성 약제조성물 및 그의 제조방법
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
EP1341524B1 (de) * 2000-12-07 2011-10-19 Nycomed GmbH Pharmazeutische zubereitung in form einer paste mit einem säurelabilen wirkstoff
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
AU2002234545A1 (en) * 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical preparation in the form of a suspension comprising an acid-labileactive ingredient
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
KR20040029966A (ko) * 2001-02-02 2004-04-08 테바 파마슈티컬 인더스트리즈 리미티드 치환된 2-(2-피리딜메틸)설피닐-１ｈ-벤즈이미다졸
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
JP4310605B2 (ja) 2001-05-25 2009-08-12 大塚製薬株式会社 医薬用組成物
US6926907B2 (en) * 2001-06-01 2005-08-09 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB0120123D0 (en) * 2001-08-17 2001-10-10 Upperton Ltd Preparation of microparticles
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
EP1572151A1 (de) * 2002-07-03 2005-09-14 Abbott Laboratories Flüssige dosierformen von protonenpumpeninhibitoren
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
RS52908B (en) 2003-03-10 2014-02-28 Takeda Gmbh NEW PROCEDURE FOR OBTAINING ROFLUMILAST
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
EP1648417A4 (de) * 2003-07-18 2010-01-20 Santarus Inc Pharmazeutische formulierung und verfahren zur behandlung von säurebedingten gastrointestinalen erkrankungen
MXPA06000529A (es) * 2003-07-18 2006-08-11 Santarus Inc Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para elaborarlas y utilizarlas.
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
EP1667681A4 (de) * 2003-10-03 2009-09-30 Astron Res Pvt Ltd Neues transmukosales abgabesystem
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
BRPI0416534A (pt) 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
WO2005053640A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
CA2547774A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
CN1889931A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾－冻凝方法
ES2600577T3 (es) * 2003-12-04 2017-02-09 Bend Research, Inc. Procedimiento de pulverización-solidificación que usa un extrusor para preparar composiciones en multipartículas de fármacos cristalinos
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
AU2005213472A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
US20050214370A1 (en) * 2004-03-26 2005-09-29 Sarama Robert J Stable coating agent comprising sterol
TR201909238T4 (tr) * 2004-03-29 2019-07-22 Wyeth Llc Multi-vitamin ve mineral besin takviyeleri.
US8968768B2 (en) 2004-03-29 2015-03-03 Wyeth Llc Phytosterol nutritional supplements
WO2005117870A2 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060034934A1 (en) * 2004-08-13 2006-02-16 Deguise Matthew L Agglomeration of sterol particles
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP2417986A1 (de) 2004-11-22 2012-02-15 Anadis Ltd. Bioaktive Zusammensetzungen
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
WO2006097456A1 (en) * 2005-03-16 2006-09-21 Nycomed Gmbh Taste masked dosage form containing roflumilast
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
EP1747776A1 (de) * 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische Zubereitung mit granulatförmigem Pantoprazol
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN104825397A (zh) * 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
PL2046334T3 (pl) 2006-07-25 2015-02-27 Vecta Ltd Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US9220698B2 (en) 2008-09-09 2015-12-29 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
EP2338477A1 (de) * 2009-12-15 2011-06-29 bene-Arzneimittel GmbH Zäpfchen mit Pantoprazol
WO2012028745A1 (en) * 2010-09-03 2012-03-08 Pharmaterials Limited Pharmaceutical composition suitable for use in a dry powder inhaler
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2012171540A1 (en) * 2011-06-15 2012-12-20 Bene-Arzneimittel Gmbh Suppository comprising pantoprazole comprised in pellets with a cellulose core
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
CN117338729B (zh) * 2023-12-06 2024-02-13 山东国邦药业有限公司 一种硫氰酸红霉素可溶性颗粒及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB931147A (en) * 1959-10-23 1963-07-10 Olin Mathieson Sustained release pharmaceutical preparations and methods for their manufacture
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
JPH05194224A (ja) * 1992-09-17 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
TW359614B (en) * 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
DE69424487T2 (de) * 1993-09-09 2001-01-18 Takeda Chemical Industries Ltd Formulierung enthaltend einen antibakteriellen und einen Antiulcus Wirkstoff
JPH07145053A (ja) * 1993-11-25 1995-06-06 Yoshitomi Pharmaceut Ind Ltd 坐 剤
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2316333T3 (es) * 1994-07-08 2009-04-16 Astrazeneca Ab Forma de dosificacion en tabletas constituida por unidades multiples.
GB2290965A (en) * 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
GB9710800D0 (en) 1997-05-23 1997-07-23 Cipla Limited Pharmaceutical composition and method of preparing it
HUP0100043A2 (hu) * 1997-12-08 2001-08-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Savérzékeny hatóanyagot tartalmazó új gyógyszerforma
SE9704869D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
DE19848849A1 (de) 1998-10-22 2000-04-27 Knoll Ag Verfahren zur Herstellung von festen, sphärischen Formen, enthaltend eine biologisch aktive Substanz

Also Published As

Publication number Publication date
HUP0100043A2 (hu) 2001-08-28
AU748209B2 (en) 2002-05-30
IL136285A0 (en) 2001-05-20
EP1037607B1 (de) 2004-02-25
CA2312493A1 (en) 1999-06-17
DE69842173D1 (de) 2011-04-21
DE69821976D1 (de) 2004-04-01
SI1037634T1 (sl) 2006-02-28
AU2413099A (en) 1999-06-28
ATE500815T1 (de) 2011-03-15
JP2001525366A (ja) 2001-12-11
EP1371361A1 (de) 2003-12-17
ES2392684T3 (es) 2012-12-12
EE04800B1 (et) 2007-04-16
EE200000329A (et) 2001-08-15
ATE260090T1 (de) 2004-03-15
US20020090397A1 (en) 2002-07-11
DE69831504D1 (de) 2005-10-13
IL136249A0 (en) 2001-05-20
ES2249849T3 (es) 2006-04-01
US6607742B2 (en) 2003-08-19
EP1037634B1 (de) 2005-09-07
JP4612184B2 (ja) 2011-01-12
IL136249A (en) 2007-07-04
DK1037607T3 (da) 2004-06-21
EP1525882B1 (de) 2012-08-08
US20020025342A1 (en) 2002-02-28
SI1037607T1 (en) 2004-08-31
JP2001525355A (ja) 2001-12-11
EP1037607A1 (de) 2000-09-27
AU751066B2 (en) 2002-08-08
WO1999029299A1 (en) 1999-06-17
EP1371361B1 (de) 2011-03-09
US6328993B1 (en) 2001-12-11
PL341054A1 (en) 2001-03-26
PL196163B1 (pl) 2007-12-31
EP1525882A1 (de) 2005-04-27
PT1037607E (pt) 2004-07-30
PL341055A1 (en) 2001-03-26
PL195266B1 (pl) 2007-08-31
CA2310585C (en) 2005-08-23
ES2362418T3 (es) 2011-07-05
DE69821976T2 (de) 2004-12-16
DK1037634T3 (da) 2005-12-19
US6383510B1 (en) 2002-05-07
US6884437B2 (en) 2005-04-26
AU2160099A (en) 1999-06-28
WO1999029320A1 (en) 1999-06-17
CA2310585A1 (en) 1999-06-17
EE200000331A (et) 2001-08-15
ATE303809T1 (de) 2005-09-15
ES2216351T3 (es) 2004-10-16
CA2312493C (en) 2007-03-06
EP1037634A1 (de) 2000-09-27
US20040022854A1 (en) 2004-02-05
EE04576B1 (et) 2006-02-15
HUP0100065A2 (hu) 2001-08-28
US6569453B2 (en) 2003-05-27
JP4546643B2 (ja) 2010-09-15

Similar Documents

Publication Publication Date Title
DE69831504T2 (de) Orale verabreichungsform enthaltend einen protonenpumpeninhibitor (z.b.pantoprazole)
ES2175066T3 (es) Antagonistas triciclicos de la vasopresina.
ITRM920476A0 (it) Formulazioni galeniche contenenti ciclosporina.
ITRM920417A1 (it) Procedimento per prelevare un carico da una pila.
DK1105105T3 (da) Oral administrationsform til pyridin-2-ylmethylsulfinyl-1H-benzimidazoler
IT1243193B (it) Composizioni farmaceutiche orali a base di melatonina
ATE450254T1 (de) Schwimmende pharmazeutische zusammensetzung mit einer aktiven phase und einer inaktiven phase
DE69625230D1 (de) Thrombininhibitoren
FI920076A0 (fi) Foerbaettrad tillslutningsmekanism foer verktyg, som anvaends foer att placera en foerslutning pao en bandfog.
PT1244643E (pt) Inibidores da triptase
FI933507A0 (fi) Bicyklopolyazamakrocyklofosfonsyror, komplex och konjugat daerav att anvaendas som kontrastmedel och foerfarande foer deras framstaellning
FI915142A0 (fi) Aktivt bullerdaempningssystem.
FI952906A0 (fi) Foerfarandet foer att foermedla informationen, som inte hoer till samtalet och terminalen
KR920000835U (ko) 화장실 등에 사용되는 부스 (Booth)
FI882260A (fi) Faergbytes- och tvaettfoerfarande foer att anvaendas i en anordning foer utbredning av belaeggningsaemne, foerdelaktigt maolfaerg och anlaeggning foer anvaendning vid foerfarandet.
ES2107607T3 (es) Tiazolilpirroles que tienen una actividad fungicida.
ATE227571T1 (de) Thrombin inhibitoren
FI902307A0 (fi) Anordning och foerfarande foer att aostadkomma hoegtrycksvaetska som skall anvaendas vid spritsvattenskaerning.
FI901925A (fi) Foerfarande och anordning foer att foerbaettra beroeringen mellan en uppsamlingsanordning och det vaetskeformade aemne, exempelvis olja, som skall uppsamlas.
NO20075921L (no) Benzimidazoldenvater som modulerer kjemokinreseptorer
FI931345A0 (fi) Tjuvalarm, som aktiveras av foeremaolets, som skall skyddas, roerelse
FI901527A0 (fi) Foerfarande och anordning foer att utveckla turbulens och diffusion i inloppslaodan av en pappersmaskin.
FI914964A0 (fi) Foerfarande foer reparation av raefflan som slitits av sugvalsens aendtaetning i en pappersmaskin.
ITTO940990A0 (it) Dispositivo per l'ancoraggio reciproco di una coppia di piastre, particolarmente di un gruppo multiconnettore ad innesti rapidi.
FI910348A0 (fi) Foerfarande foer reparering av koerspaor, som uppstaor i vaegars permanent belaeggning.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NYCOMED GMBH, 78467 KONSTANZ, DE